The PennZone

  • Home
  • Music
  • Entertainment
  • Marketing
  • Non-profit
  • Education
  • Technology
  • Event
  • Books

ExpressCells Named Most Fundable Company by Pepperdine Graziadio Business School
The PennZone/10088820

Trending...
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
  • Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform
PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone
  • Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
  • LATO AI Software Innovations Expedite Inspections & Repair of Parking Lots for The Pavement Group
  • Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
  • Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
  • Contracting Resources Group Named to Inc. 5000 for the Ninth Time

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone
  • Nola Blue Records to Release John Németh's Illinois Central in March 2027
  • ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
  • ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
  • The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
  • PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
Matt Handel
***@xpresscells.com


Source: ExpressCells

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Insurance for Braces Helps Make Treatment More Manageable for Pennsylvania Families
  • Black Ribbon Productions Launches With Fearless 2026 Horror Slate
  • Actor Dominic Pace Returns to Television and Film
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services
  • Silicon Box Ships 500M Units at High Yield, Expands Production Capacity for Panel-Level Packaging
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
  • Meals on Wheels of the Greater Lehigh Valley Awarded $50,000 Grant from Harry C. Trexler Trust
  • RPR Promotes Emily Line to Chief Strategy Officer and Janine Sieja to Chief Product Officer
  • Kellyn Hosts Fourth Lehigh Valley Lifestyle Medicine Symposium
  • Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat
  • Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform
  • Racquet Club of Philadelphia appoints Michael J. Sofia as new General Manager
  • Cellofest Brings Free Cello Concerts and Community Events to Bethany Beach August 5–16
  • Blue Sky Capital Strategies, LLC awarded Leasing and Financial Services agreement with Premier Inc
  • Michael M. Thomas Expands Executive Leadership Across Central India Outreach and Royal Trinity School
  • Porter's Day Care Opens Doors to Brighter Futures
  • Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
  • RevOtter Names Levi Bilbrey CEO, as Company Expands Fractional CMO, RevOps and Web Design Services

Popular on PennZone

  • Community Partnership Brings Live Theater to 150+ Young People
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
  • Cogs and Marvel expands EMEA leadership team for next phase of growth
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio

Similar on PennZone

  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us